Ascendis Pharma/$ASND
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ascendis Pharma
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
Ticker
$ASND
Sector
Primary listing
Industry
Biotechnology
Headquarters
Hellerup, Denmark
Employees
1,017
ISIN
US04351P1012
Website
Ascendis Pharma Metrics
BasicAdvanced
$10B
-
-$6.71
0.40
-
Price and volume
Market cap
$10B
Beta
0.4
52-week high
$183.00
52-week low
$111.09
Average daily volume
435K
Financial strength
Current ratio
1.041
Quick ratio
0.672
Long term debt to equity
-188.25
Total debt to equity
-446.386
Interest coverage (TTM)
-10.08%
Profitability
EBITDA (TTM)
-379.042
Gross margin (TTM)
85.30%
Net profit margin (TTM)
-92.67%
Operating margin (TTM)
-90.54%
Effective tax rate (TTM)
-1.00%
Revenue per employee (TTM)
$414,970
Management effectiveness
Return on assets (TTM)
-22.39%
Return on equity (TTM)
159.67%
Valuation
Price to revenue (TTM)
23.568
Price to book
-54.3
Price to tangible book (TTM)
-53.2
Price to free cash flow (TTM)
-39.344
Free cash flow yield (TTM)
-2.54%
Free cash flow per share (TTM)
-433.89%
Growth
Revenue change (TTM)
12.06%
Earnings per share change (TTM)
-34.42%
3-year revenue growth (CAGR)
198.52%
10-year revenue growth (CAGR)
40.77%
3-year earnings per share growth (CAGR)
-10.19%
10-year earnings per share growth (CAGR)
26.60%
What the Analysts think about Ascendis Pharma
Analyst ratings (Buy, Hold, Sell) for Ascendis Pharma stock.
Bulls say / Bears say
Ascendis Pharma's hypoparathyroidism drug, Yorvipath, received FDA approval, positioning it as the first and only treatment for this condition, potentially capturing significant market share. (Benzinga)
The company secured a $150 million royalty funding agreement with Royalty Pharma, providing substantial capital to support the development and commercialization of its Endocrine Rare Disease products. (GlobeNewswire)
Analysts maintain a 'buy' rating on Ascendis Pharma, with a consensus 12-month price target of $196, indicating confidence in the company's growth prospects. (TradingView News)
Ascendis Pharma reported a 27% year-over-year decline in Skytrofa sales, leading to a downward revision of its full-year 2024 sales guidance from €320-340 million to €220-240 million. (Benzinga)
The company posted a quarterly adjusted loss of €0.64 per share, missing analyst expectations and indicating ongoing profitability challenges. (TradingView News)
Ascendis Pharma's stock experienced an 11% decline following the earnings miss and reduced guidance, reflecting investor concerns over the company's financial performance. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
Ascendis Pharma Financial Performance
Revenues and expenses
Ascendis Pharma Earnings Performance
Company profitability
Ascendis Pharma News
AllArticlesVideos
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
GlobeNewsWire·2 weeks ago
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
Accesswire·1 month ago
Cerrado Gold and Ascendant Resources Announce Completion of Business Combination Transaction
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ascendis Pharma stock?
Ascendis Pharma (ASND) has a market cap of $10B as of June 20, 2025.
What is the P/E ratio for Ascendis Pharma stock?
The price to earnings (P/E) ratio for Ascendis Pharma (ASND) stock is 0 as of June 20, 2025.
Does Ascendis Pharma stock pay dividends?
No, Ascendis Pharma (ASND) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Ascendis Pharma dividend payment date?
Ascendis Pharma (ASND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ascendis Pharma?
Ascendis Pharma (ASND) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.